Get Unlimited Plan at 75% OFF!
Solara Active Pharma Sciences
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Solara Active Pharma Sciences Ltd is a Public Limited Company incorporated in February 23, 2017 under the provisions of Companies Act, 2013 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has six APIs manufacturing plants located in Ambernath, Mangalore, Mysore, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,000 kilo litres and two R&D Centres in Chennai and Bangalore. The business is spread across 75 countries globally with extensive operations in key markets of North America, Europe, Japan, South Korea, the Middle East and North Africa.
The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others. It also reinforce entry barriers to competition and build strong intrinsic value through market specific launches. Apart from this, the Solara Active has two research and development units - in Bengaluru and Chennai - equipped with state-of-the-art facilities and a pipeline of 25+ products, at different stages of development. These drugs primarily deal with anthelmintic, anti-malarias, beta blockers, muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.
The Company's manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA); European Directorate for the Quality of Medicines (EDQM); Korea Food & Drug Administration (KFDA) - South Korea; Euro Zone - Good Manufacturing Practice (EUGMP) - Danish, World Health Organization (WHO) - Geneva; Medicines and Healthcare products Regulatory Agency (MHRA); Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico; Therapeutic Goods Administration (TGA) - Australia; Pharmaceuticals and Medical Devices Agency (PMDA) - Japan.
During the year, the Company's wholly owned subsidiary Strides Chemicals Private Limited (Strides Chemicals) was amalgamated with the Company. The Honourable National Company Law Tribunal, Mumbai Bench, approved the Scheme of Amalgamation of Strides Chemicals with Company on December 20, 2019. Accordingly, the Company has fixed effective date for the Scheme is February 01, 2020. The appointed date for scheme is September 01, 2018. The Company has completed filing of necessary documents for giving effect to the Scheme. Consequent to amalgamation, the entire equity shares held by Company in Strides Chemicals stands cancelled.
The Board of Directors of Company at its meeting held on April 09, 2021 have approved Scheme of Amalgamation for merger of Aurore Life Science Private Limited, Empyrean Lifesciences Private Limited and Hydra Active Pharma Sciences Private Limited (Transferor Companies) into the Company (Transferee Company) in terms of Section 230 to 232 of the Companies Act, 2013. The Scheme is subject to necessary statutory and regulatory approvals including the approvals of National Company Law Tribunal, the shareholders and creditors of each of the companies. The Appointed Date for the said Scheme of Amalgamation is April 01, 2021 or such other date as may be agreed between the Transferor Company and Transferee Company and approved by National Company Law Tribunal.
The Company's new Greenfield plant situated at SEZ unit, Plot No.:3B,3C,3D, Part 2 and 2A-1, APIIC APSEZ, Atchutapuram Village, Rambilli Mandal, Visakhapatnam - 531011, Andhra Pradesh, has commenced commercial production in 2021.
The Board at its meeting held on February 3, 2021 has approved to acquire 4,87,000 additional share capital in Sequent Penems Private Limited, subsidiary company of Solara. Subsequent to year end, the said transaction is completed and Sequent Penems Private Limited is wholly owned subsidiary of Company with effect from April 27, 2021.
The achievements received by the Company in FY 2020-21 were as follows: The Ambernath facility received Certificate of Merit from National Safety Council, Maharashtra for Lowest Average Accident Frequency Rate'. They improved EcoVadis Score from 31 to 47 and was awarded a bronze medal in recognition of Sustainability achievement. The Mangalore site of company was certified for ISO 14001 and ISO 45001. Besides, they conducted a Red Tag Event to identify unsafe conditions and acts to make workplace injury nd incident free. All employees and contractors actively participated in the event.
.
Solara Active Pharma Sciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Solara Active Pharma Sciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Solara Active Pharma Sciences is valued compared to its competitors.
Solara Active Pharma Sciences PE ratio helps investors understand what is the market value of each stock compared to Solara Active Pharma Sciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Solara Active Pharma Sciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Solara Active Pharma Sciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Solara Active Pharma Sciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Solara Active Pharma Sciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Solara Active Pharma Sciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Solara Active Pharma Sciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Solara Active Pharma Sciences helps investors get an insight into when they can enter or exit the stock. Key components of Solara Active Pharma Sciences Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Solara Active Pharma Sciences shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Solara Active Pharma Sciences ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Solara Active Pharma Sciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Solara Active Pharma Sciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Solara Active Pharma Sciences .
The balance sheet presents a snapshot of Solara Active Pharma Sciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App